uniQure N.V. (QURE)

4,4100 +0,0200 (+0,46%) Al cierre: 04:00PM EDT

uniQure N.V.

Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 480

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Matthew Craig Kapusta	CEO & Executive Director	1,02M	N/A	1972
Mr. Christian Klemt	CFO, Principal Financial Officer & GM of Amsterdam Site	575,46k	N/A	1973
Mr. Pierre Caloz	Chief Operating Officer	882,59k	N/A	1973
Mr. Richard Porter Ph.D.	Chief Business & Scientific Officer	732,17k	N/A	1968
Dr. Jeannette Potts J.D., Ph.D.	Chief Legal & Compliance Officer and Corporate Secretary	635,56k	N/A	1962
Prof. Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	N/A	N/A	N/A
Dr. Tamara Tugal Ph.D., MBA	Business Development Director	N/A	N/A	N/A
Ms. Carla Poulson	Interim Chief People and Culture Officer	N/A	N/A	N/A
Ms. Maria E. Cantor	Chief Corporate Affairs Officer	491,12k	N/A	1968
Dr. Amin Abujoub Ph.D.	Chief Quality Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Gobierno corporativo

El ISS Governance QualityScore de uniQure N.V., a día 29 de abril de 2024, es 2. Las puntuaciones base son Auditoría: 4; Tablero: 3; Derechos de los accionistas: 1; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.